The HRD Decision - Which PARP Inhibitor to Use for Whom and When

Clin Cancer Res. 2017 Dec 1;23(23):7155-7157. doi: 10.1158/1078-0432.CCR-17-2186. Epub 2017 Oct 3.

Abstract

Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. Clin Cancer Res; 23(23); 7155-7. ©2017 AACRSee related article by Balasubramaniam et al., p. 7165.

Publication types

  • Comment

MeSH terms

  • Female
  • Humans
  • Indoles
  • Mutation / drug effects
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms*
  • Poly(ADP-ribose) Polymerase Inhibitors*

Substances

  • Indoles
  • Poly(ADP-ribose) Polymerase Inhibitors
  • rucaparib